Surveyed docs see need for new prostate-cancer meds, Medivation says

Medivation ($MDVN), which is developing a new treatment for prostate cancer, said a European survey found that doctors see a need for new treatments that extend patients' lives, with 85% of oncologists and 74% of urologists calling overall survival benefits the most important attribute of a new treatment. Release